Bristol-Myers Loses ImClone but Gains $1 Billion

Bristol-Myers lost ImClone to a higher bidder. But the deal allows Bristol to cash out of its 17% stake in ImClone for $1 billion, while continuing to receive a large slice of the revenues from ImClone's drug Erbitux.